A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance - Top_Thought_Leaders - MDSpire

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

Approximately 3% to 4% of the population over the age of 50 is diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It carries a lifelong risk of progression to multiple myeloma and lymphoma, requiring risk-adapted monitoring by multidisciplinary teams.

  • By

  • Kimberly Noonan

  • Kevin Brigle

  • Charise Gleason

  • Carrie Bellerive

  • Mary Steinbach

  • Deborah Doss

  • March 4, 2026

  • 17 min

Share

Top Thought Leaders in Urology

Brief introduction explaining scope and methodology.

Original Source(s)

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

  • by Kimberly Noonan, Kevin Brigle, Charise Gleason, Carrie Bellerive, Mary Steinbach, Deborah Doss

  • March 4, 2026

Related Content

Roswell Park Researchers to Discuss Recent Discoveries and Critical Issues in Oncology at AACR 2025

Researchers from Roswell Park Comprehensive Cancer Center will report their latest findings to colleagues from around the world at the 2025 annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois, April 25-30.

  • by

  • April 25, 2025

  • 11 min
Biochemical Tumor Markers: Are New Testing Guidelines Fit for Purpose?

CLSI guidance achieves technical excellence but has some questionable omissions, says Mustafa Barbhuiya

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

  • February 26, 2025

  • 1 min